Previous close | 14.62 |
Open | 14.87 |
Bid | 15.46 x 200 |
Ask | 15.59 x 100 |
Day's range | 14.62 - 15.81 |
52-week range | 3.35 - 16.66 |
Volume | |
Avg. volume | 1,430,150 |
Market cap | 806.816M |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 20, 2024, Edward M. Kaye, MD, Chief Executive Officer of Stoke Therapeutics Inc (NASDAQ:STOK), executed a significant stock transaction, selling 42,350 shares of the company.
Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
Stoke Therapeutics ( NASDAQ:STOK ) First Quarter 2024 Results Key Financial Results Net loss: US$26.4m (loss widened by...